Results 211 to 220 of about 176,622 (333)

Bevacizumab in Pediatric Neuro-Oncology. [PDF]

Curr Oncol
Silverman J, Sathyakumar S, Coltin H, Perreault S, Jabado N, Bouffet E, Renzi S.   +6 more
europepmc   +1 more source

Regression of choroidal metastasis secondary to breast carcinoma with adjuvant intravitreal injection of bevacizumab [PDF]

, 2009
Hsin‐Yu Yao, Chi‐Ting Horng, Jiann‐Torng Chen, Ming‐Ling Tsai   +3 more
openalex   +1 more source

Review of Retinopathy of Prematurity Management in the Anti‐VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI‐Assisted Future

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Retinopathy of prematurity (ROP) remains a major cause of preventable blindness in premature infants worldwide, with increasing incidence due to advancements in neonatal care. Management of ROP has been revolutionised by anti‐vascular endothelial growth factor (anti‐VEGF) treatments.
Kyle V. Marra, Jimmy S. Chen, Eric Nudleman, Shira L. Robbins   +3 more
wiley   +1 more source

Network Meta-Analysis of Bevacizumab Gamma Versus Competing Interventions for Treating Neovascular Age-Related Macular Degeneration in the United Kingdom. [PDF]

J Mark Access Health Policy
Lorenzi M, Ebohon S, Kissner J, Comiskey J, Paap M, Bouchet C, Garnham A, Wissinger E.   +7 more
europepmc   +1 more source

Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab

, 2014
Morteza Entezari, Alireza Ramezani, Hamid Ahmadieh, Hassan Ghasemi   +3 more
openalex   +1 more source

Ten‐Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age‐Related Macular Degeneration

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To evaluate the 10‐year cumulative incidence, progression rates, and risk factors for macular atrophy (MA) in neovascular age‐related macular degeneration (nAMD) patients receiving long‐term anti‐vascular endothelial growth factor (VEGF) therapy.
Francesco Romano, Marco Casaluci, Antonio Valastro, Matteo Airaldi, Paolo Milella, Francesco Pozzo Giuffrida, Elisa Cozzi, Andrea Aretti, Kelvin YC Teo, Chui Ming Gemmy Cheung, Marco Nassisi, Francesco Viola, Giovanni Staurenghi, Alessandro Invernizzi   +13 more
wiley   +1 more source

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. [PDF]

Saudi Pharm J
Shan H, Guo Z, Ye X, Du Q, Liu J, Wang M.   +5 more
europepmc   +1 more source

Efficacy of the combined use of bevacizumab and irinotecan in a human colorectal cancer xenograft model analysed by SPECT imaging [PDF]

, 2011
Geboes, Karen, Laurent, Stéphanie, Peeters, Marc, Van Damme, Nancy, Van De Wiele, Christophe, VANGESTEL, CHRISTEL   +5 more
core   +1 more source

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis

Hongfu Cai, Ling Fang, Jingwen Lin, Zhiwei Zheng   +3 more
openalex   +1 more source

Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion

, 2013
Mehmet Demir, Burcu Dirim, Zeynep Acar, Selam Yekta Şendül, Ersin Oba   +4 more
openalex   +1 more source